With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

AbbVie, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Sales of the Trikafta/Kaftrio approached $1 billion in the third quarter, driving a 62% increase in revenues at the company even as even as Vertex' older therapies started to decline.

Vertex's CF therapies account for the bulk of its revenues and are predicted to reach $10 billion in 2024, driven by triple therapy Trikafta/Kaftrio (elexacaftor, ivacaftor, and tezacaftor), which ...

Vertex Pharmaceuticals Share Price Live Today:Get the Live stock price of VRTX Inc., and quote, performance, latest news to help you with stock trading and investing.Check out why Vertex ...